Audentes Therapeutics (BOLD) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 6, 2018 4:01 PM ESTSAN FRANCISCO, Nov. 6, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today reported its financial results for the third quarter ended September 30, 2018 and provided an update on the company's recent achievements and upcoming milestones.
"In the third quarter, we continued to see exciting progress in the clinical development of AT132," stated Matthew R. Patterson, Chairman and Chief Executive Officer. "We recently presented new ASPIRO data at the 23rd International Annual Congress of the... More
